<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Aquestive Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/aquestive-therapeutics-inc</link>
<description>Latest news and press releases for Aquestive Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 30 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/aquestive-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835476c78dffbe2df0e364b.webp</url>
<title>Aquestive Therapeutics Inc</title>
<link>https://6ix.com/company/aquestive-therapeutics-inc</link>
</image>
<item>
<title>Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film</title>
<link>https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-announces-completion-of-type-a-meeting-with-fda-for-anaphylmtm-dibutepinephrine-sublingual-film</link>
<guid isPermaLink="true">https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-announces-completion-of-type-a-meeting-with-fda-for-anaphylmtm-dibutepinephrine-sublingual-film</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>Reaffirms guidance to resubmit the Anaphylm NDA in Q3 2026Received clarifying feedback from the FDA on pharmacokinetic (PK) and human factor (HF) study</description>
</item>
<item>
<title>Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer</title>
<link>https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-announces-new-role-of-lori-j-braender-and-appointment-of-thomas-a-zalewski-as-chief-legal-officer-and-chief-compliance-officer</link>
<guid isPermaLink="true">https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-announces-new-role-of-lori-j-braender-and-appointment-of-thomas-a-zalewski-as-chief-legal-officer-and-chief-compliance-officer</guid>
<pubDate>Fri, 20 Mar 2026 11:00:00 GMT</pubDate>
<description>Thomas A. Zalewski, a Partner at Day Pitney LLP, appointed Chief Legal Officer and Chief Compliance Officer effective April 2, 2026Lori J. Braender to remain in a non-executive role as Corporate Secretary after nearly eight years as Chief Legal Officer, Chief Compliance Officer and Corporate Secretary WARREN, N.J., March 20, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improve</description>
</item>
<item>
<title>Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-announces-grant-of-inducement-award-pursuant-to-nasdaq-listing-rule-5635c4-4</link>
<guid isPermaLink="true">https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-announces-grant-of-inducement-award-pursuant-to-nasdaq-listing-rule-5635c4-4</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company</description>
</item>
<item>
<title>Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update-60</link>
<guid isPermaLink="true">https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update-60</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026; Type A meeting with FDA expected to occur within 30 daysOn track</description>
</item>
<item>
<title>Aquestive Therapeutics to Participate in Upcoming March Investor Conferences</title>
<link>https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-to-participate-in-upcoming-march-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-to-participate-in-upcoming-march-investor-conferences</guid>
<pubDate>Wed, 25 Feb 2026 12:00:00 GMT</pubDate>
<description>WARREN, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in four upcoming investor conferences in March as follows: TD Cowen 46th Annual Health Care Conference: Management will be available for 1x1 meetings on Tuesday, March 3</description>
</item>
<item>
<title>Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET</title>
<link>https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-to-report-fourth-quarter-2025-financial-results-and-recent-business-highlights-on-march-4-and-host-conference-call-on-march-5-at-800-am-et</link>
<guid isPermaLink="true">https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-to-report-fourth-quarter-2025-financial-results-and-recent-business-highlights-on-march-4-and-host-conference-call-on-march-5-at-800-am-et</guid>
<pubDate>Tue, 24 Feb 2026 12:00:00 GMT</pubDate>
<description>WARREN, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the fourth quarter ended December 31, 2025 and provide an update on recent developments in its business after market close on Wednesday, March 4, 2026. Management will host a con</description>
</item>
<item>
<title>Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
<link>https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-to-participate-in-oppenheimer-36th-annual-healthcare-life-sciences-conference</link>
<guid isPermaLink="true">https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-to-participate-in-oppenheimer-36th-annual-healthcare-life-sciences-conference</guid>
<pubDate>Mon, 23 Feb 2026 12:00:00 GMT</pubDate>
<description>WARREN, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in the upcoming Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, which is a virtual event. The Aquestive team will be presenting on Februar</description>
</item>
<item>
<title>Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting</title>
<link>https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-to-present-new-clinical-data-on-anaphylmtm-dibutepinephrine-sublingual-film-at-the-2026-aaaai-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-to-present-new-clinical-data-on-anaphylmtm-dibutepinephrine-sublingual-film-at-the-2026-aaaai-annual-meeting</guid>
<pubDate>Fri, 20 Feb 2026 05:00:00 GMT</pubDate>
<description>Anaphylm™ (dibutepinephrine) sublingual film achieved clinically relevant epinephrine plasma concentrations without diastolic blood pressure dip WARREN, N.J.,</description>
</item>
<item>
<title>Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer</title>
<link>https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-appoints-internationally-recognized-allergist-dr-matthew-greenhawt-as-chief-medical-officer</link>
<guid isPermaLink="true">https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-appoints-internationally-recognized-allergist-dr-matthew-greenhawt-as-chief-medical-officer</guid>
<pubDate>Wed, 18 Feb 2026 05:00:00 GMT</pubDate>
<description>Board-certified allergist and leading food allergy and anaphylaxis researcher joins Aquestive to support Anaphylm™ (dibutepinephrine) sublingual film NDA</description>
</item>
<item>
<title>Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™</title>
<link>https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-announces-fda-issuance-complete-response-letter-anaphylmtm</link>
<guid isPermaLink="true">https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-announces-fda-issuance-complete-response-letter-anaphylmtm</guid>
<pubDate>Mon, 02 Feb 2026 05:00:00 GMT</pubDate>
<description>Deficiencies limited to packaging and administrationCompany believes it can rapidly resolve deficiencies and expects to resubmit as early as Q3 2026Remains</description>
</item>
<item>
<title>Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update</title>
<link>https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-announces-regulatory-development-anaphylmtm-dibutepinephrine</link>
<guid isPermaLink="true">https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-announces-regulatory-development-anaphylmtm-dibutepinephrine</guid>
<pubDate>Fri, 09 Jan 2026 05:00:00 GMT</pubDate>
<description>Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discussions for Anaphylm at this time Receives confirmation from</description>
</item>
<item>
<title>Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-participate-piper-sandler-37th-annual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-participate-piper-sandler-37th-annual-healthcare-conference</guid>
<pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
<description>WARREN, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing</description>
</item>
<item>
<title>Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-reports-third-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-reports-third-quarter-2025-financial-results-and-provides</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>Planned U.S. launch of Anaphylm™ in the first quarter of 2026, if approved by the FDA Advanced Anaphylm regulatory activities in Canada and the EUAdded</description>
</item>
<item>
<title>Aquestive Therapeutics Announces Leadership Expansion to Support Growth</title>
<link>https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-announces-leadership-expansion-support-growth-2025-11-04</link>
<guid isPermaLink="true">https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-announces-leadership-expansion-support-growth-2025-11-04</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>Changes strategically aligned to support planned launch of Anaphylm™ (dibutepinephrine) Sublingual Film, if approved by the FDA, and to accelerate the</description>
</item>
<item>
<title>Aquestive Therapeutics to Participate in a Fireside Chat Hosted by Piper Sandler</title>
<link>https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-participate-fireside-chat-hosted-piper-sandler-2025-11-03</link>
<guid isPermaLink="true">https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-participate-fireside-chat-hosted-piper-sandler-2025-11-03</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>WARREN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing</description>
</item>
<item>
<title>Aquestive Therapeutics to Attend 2025 ACAAI Annual Meeting</title>
<link>https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-attend-2025-acaai-annual-meeting-2025-10-30</link>
<guid isPermaLink="true">https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-attend-2025-acaai-annual-meeting-2025-10-30</guid>
<pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
<description>WARREN, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing</description>
</item>
<item>
<title>Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET</title>
<link>https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-report-third-quarter-2025-financial-results-and-recent</link>
<guid isPermaLink="true">https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-report-third-quarter-2025-financial-results-and-recent</guid>
<pubDate>Mon, 27 Oct 2025 04:00:00 GMT</pubDate>
<description>WARREN, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing</description>
</item>
<item>
<title>Aquestive Therapeutics Broadens Patent Estate for Anaphylm™</title>
<link>https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-broadens-patent-estate-anaphylmtm-2025-10-08</link>
<guid isPermaLink="true">https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-broadens-patent-estate-anaphylmtm-2025-10-08</guid>
<pubDate>Wed, 08 Oct 2025 04:00:00 GMT</pubDate>
<description>New patents extend protection for Anaphylm™ into 2037Anaphylm (dibutepinephrine) Sublingual Film, if approved by the FDA, will be the first and only oral</description>
</item>
<item>
<title>Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™</title>
<link>https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-announces-fda-will-not-require-advisory-committee-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-announces-fda-will-not-require-advisory-committee-meeting</guid>
<pubDate>Thu, 04 Sep 2025 04:00:00 GMT</pubDate>
<description>NDA remains on track for FDA PDUFA goal date of January 31, 2026Commercial planning continues enabling rapid launch following approval WARREN, N.J., Sept. 04,</description>
</item>
<item>
<title>Aquestive Therapeutics to Participate in Upcoming September Investor Conferences</title>
<link>https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-participate-upcoming-september-investor-conferences-2025-08-26</link>
<guid isPermaLink="true">https://6ix.com/company/aquestive-therapeutics-inc/news/aquestive-therapeutics-participate-upcoming-september-investor-conferences-2025-08-26</guid>
<pubDate>Tue, 26 Aug 2025 04:00:00 GMT</pubDate>
<description>WARREN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing</description>
</item>
</channel>
</rss>